THE FIBRINOLYTIC SYSTEM IN HUMAN ASCITES

被引:5
作者
BUO, L
KARLSRUD, TS
DYRHAUG, G
BELL, H
ENGSTROM, L
JOHANSEN, HT
AASEN, AO
机构
[1] UNIV OSLO, INST PHARM, DEPT PHARMACOL, OSLO, NORWAY
[2] AKER HOSP, DEPT MED, OSLO, NORWAY
[3] SODERSJUKHUSET HOSP, DEPT SURG, STOCKHOLM, SWEDEN
[4] SODERSJUKHUSET HOSP, STOCKHOLM, SWEDEN
关键词
ASCITES; FIBRINOLYSIS; LIVER FAILURE; MALIGNANCY; PLASMINOGEN ACTIVATORS;
D O I
10.3109/00365529509101614
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: We recently reported that the contact and kallikrein-kinin systems are activated in malignancy-related ascites. We have now studied the fibrinolytic system in ascites and plasma from patients with gastrointestinal cancer (n = 14) and non-malignant liver disease (n = 18). Methods and Results: Enzyme immunoassays (EIAs) showed that urokinase and tissue plasminogen activators (uPA, tPA) and PA inhibitors (PAI-1, PAI-2) were present in ascites from both patient groups and that tPA was the predominant PA. uPA, tPA, and PAI-1, but not PAI-2, were detected in plasma from patients and controls. These EIA findings were supported by zymography studies. Functional assays showed considerable generation of plasmin-like activity and low plasminogen and antiplasmin values in malignancy-related ascites. The plasmin/antiplasmin and tPA/PAI-1 ratios were particularly high in malignancy-related ascites as compared with non-malignant ascites. Plasma from the liver disease patients showed a higher tPA/PAI-1 ratio and, thus, a higher potential for plasminogen activation than plasma from cancer patients and controls. Patient plasma showed low values of plasmin-like activity, antiplasmin, and plasminogen. Conclusion: Our findings show that the fibrinolytic system is activated in malignancy-related ascites.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 46 条
[1]  
AASEN AO, 1982, ACTA CHIR SCAND, P17
[2]  
ADAMSEN S, 1991, ACTA CHIR-EUR J SURG, V157, P325
[3]  
AOKI N, 1978, CLIN CHIM ACTA, V84, P99
[4]   PLASMINOGEN ACTIVATORS IN ALCOHOLIC CIRRHOSIS - DEMONSTRATION OF INCREASED TISSUE-TYPE AND UROKINASE TYPE ACTIVATOR [J].
BOOTH, NA ;
ANDERSON, JA ;
BENNETT, B .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (07) :772-777
[5]   LOCATION OF PLASMINOGEN-ACTIVATOR (PA) AND PA INHIBITOR IN HUMAN COLORECTAL ADENOCARCINOMAS [J].
BUO, L ;
LYBERG, T ;
JORGENSEN, L ;
JOHANSEN, HT ;
AASEN, AO .
APMIS, 1993, 101 (03) :235-241
[6]   THE CONTACT SYSTEM IN HUMAN-MALIGNANT AND BENIGN ASCITES [J].
BUO, L ;
KARLSRUD, TS ;
JOHANSEN, HT ;
AASEN, AO .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1993, 53 (02) :117-124
[7]   DIFFERENTIAL-DIAGNOSIS OF HUMAN ASCITES - INHIBITORS OF THE CONTACT SYSTEM AND TOTAL PROTEINS [J].
BUO, L ;
KARLSRUD, TS ;
DYRHAUG, G ;
JACOBSEN, MB ;
BELL, H ;
JOHANSEN, HT ;
AASEN, AO .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (09) :777-782
[8]  
BUO L, 1994, ANTICANCER RES, V14, P2445
[9]  
CASSLEN B, 1992, FIBRINOLYSIS, V6, P65
[10]  
CONOVER WJ, 1980, PRACTICAL NONPARAMET, P288